Cantor Fitzgerald Lowers Stoke Therapeutics (NASDAQ:STOK) Price Target to $20.00

Stoke Therapeutics (NASDAQ:STOKGet Rating) had its price objective cut by equities researchers at Cantor Fitzgerald from $38.00 to $20.00 in a note issued to investors on Tuesday, The Fly reports. Cantor Fitzgerald’s price objective indicates a potential upside of 121.73% from the company’s previous close.

Other equities analysts have also recently issued research reports about the company. Needham & Company LLC lowered their target price on Stoke Therapeutics from $50.00 to $25.00 and set a “buy” rating for the company in a report on Monday. Credit Suisse Group reduced their price target on Stoke Therapeutics from $50.00 to $38.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, SVB Leerink upgraded Stoke Therapeutics from a “market perform” rating to an “outperform” rating and set a $30.00 price target on the stock in a research report on Monday, October 24th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $34.86.

Stoke Therapeutics Stock Down 9.7 %

Shares of STOK opened at $9.02 on Tuesday. Stoke Therapeutics has a 12-month low of $8.36 and a 12-month high of $33.06. The business has a 50-day simple moving average of $13.32 and a two-hundred day simple moving average of $14.22.

Institutional Investors Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in STOK. Ensign Peak Advisors Inc bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $25,000. Point72 Hong Kong Ltd bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $27,000. Russell Investments Group Ltd. bought a new stake in shares of Stoke Therapeutics during the 2nd quarter valued at about $28,000. UBS Group AG bought a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at about $47,000. Finally, Amalgamated Bank bought a new stake in shares of Stoke Therapeutics during the 1st quarter valued at about $66,000.

Stoke Therapeutics Company Profile

(Get Rating)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression.

Featured Stories

The Fly logo

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.